Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5825702 | Clinical Therapeutics | 2011 | 17 Pages |
Abstract
The 2 incretin drug classes provided effective and consistent glycemic control with a good tolerability profile. These agents might also improve long-term β-cell function and either reduce body weight or be weight neutral. Their role in the therapeutic armamentarium of T2DM is evolving as their potential strengths and weaknesses become better defined.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
R. Keith RPh, MBA, FASHP, CDE,